Liposome mitoxantrone with chemo before stem cell transplant for AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a chemotherapy combination (liposome mitoxantrone plus busulfan and cyclophosphamide) given before a stem cell transplant to treat acute myeloid leukemia (AML) that is either at intermediate or high risk, or has signs of remaining leukemia cells (persistent MRD). It aims to improve transplant success for patients who still have detectable disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 60 years old.
- You have acute myeloid leukemia (AML), but not a subtype called acute promyelocytic leukemia.
- Your AML is considered intermediate or high risk by standard guidelines, or tests still show leukemia cells (MRD positive) before transplant.
- You are in generally good health (ECOG score 0-2, meaning you can do daily activities).
- You do not have active hepatitis B, C, or HIV.
- You need to sign a consent form or have a close relative do it for you if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
This trial tests a combination of four chemotherapy drugs (mitoxantrone liposome, bendamustine, etoposide, and cytarabine) given before a stem cell transplant for people with lymphoma. The goal is to prepare the body for the transplant and improve outcomes.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of three drugs—mitoxantrone liposome, cytarabine, and venetoclax—for people with AML that has come back or not responded to standard treatment. It aims to see if this combination is safe and effective.
This trial tests a liposomal form of mitoxantrone combined with other drugs for people with aggressive multiple myeloma (high-risk or spread outside the bone). The goal is to see if this approach helps control the cancer better.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.